Literature DB >> 14717975

G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3'-end formation.

H Ceelie1, C C Spaargaren-van Riel, R M Bertina, H L Vos.   

Abstract

BACKGROUND: The prothrombin G20210A mutation is associated with increased plasma prothrombin levels and risk of thrombosis. The mechanism by which this mutation leads to increased prothrombin expression is as yet unclear and still the subject of debate.
OBJECTIVES: The aim of this study was to investigate the effect of the G20210A mutation on mRNA and protein expression.
METHODS: We made a set of constructs containing the prothrombin 5'-regulatory region, the firefly luciferase reporter gene and the prothrombin 3'-UTR+ downstream region. The latter element contained either the 20210G or A allele and was inserted either as a single unit (constructs G1 and A1) or in tandem (A1A2, G1G2, A1G2, G1A2). Constructs were transiently expressed in HepG2 cells. Expression was evaluated by luciferase assays and reverse transcriptase-polymerase chain reaction (RT-PCR), followed by quantification of the products and determination of the ratio of poly(A)site usage. RT-PCR sequencing was used for determination of the actual site of polyadenylation in mRNAs from constructs G1 and A1 and from endogenous prothrombin mRNAs from HepG2 cells and human liver tissue.
RESULTS: The A1 constructs expressed 1.2-fold more protein than the G1 constructs. The double constructs expressed 1.4-fold more protein (A1A2 vs. G1G2). Similar results were found in a set of constructs in which an SV40 promoter replaced the prothrombin 5'-regulatory region. Ratios of poly(A) site usage (expressed as ratio poly(A) site 1 and 2) for the tandem constructs were similar for constructs with two Gs or As at both poly(A)sites; 2.92 (95% confidence interval 2.39-3.45) and 2.75 (2.55-2.95). pA1/pA2 ratios were 1.46 (1.11-1.81) for G1A2 and 6.29 (5.48-7.10) for A1G2 constructs with different poly(A) sites, indicating that the poly(A)site with the 20210A variant is favored over the normal site. In 20210G mRNAs, the G at 20210 was the last non-A nucleotide in the majority of mRNAs, whereas in most 20210A mRNAs, the last non-A nucleotide was the C at 20209. Over 70% of the prothrombin 20210G mRNAs from HepG2 cells and human liver tissue is polyadenylated at position 20210.
CONCLUSIONS: The 20210A variant has a more effective poly(A) site, leading to increased mRNA and protein expression, irrespective of the promoter and gene. It does not affect the position of poly(A) attachment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14717975     DOI: 10.1111/j.1538-7836.2003.00493.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  22 in total

1.  Cytoplasmic stabilities of 3'UTR-polymorphic prothrombin mRNAs.

Authors:  X Liu; J E Russell
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

Review 2.  A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes I: general principles and overview.

Authors:  Jian-Min Chen; Claude Férec; David N Cooper
Journal:  Hum Genet       Date:  2006-04-28       Impact factor: 4.132

Review 3.  3' end mRNA processing: molecular mechanisms and implications for health and disease.

Authors:  Sven Danckwardt; Matthias W Hentze; Andreas E Kulozik
Journal:  EMBO J       Date:  2008-02-06       Impact factor: 11.598

Review 4.  Implications of polyadenylation in health and disease.

Authors:  Ana Curinha; Sandra Oliveira Braz; Isabel Pereira-Castro; Andrea Cruz; Alexandra Moreira
Journal:  Nucleus       Date:  2014-10-31       Impact factor: 4.197

5.  MTHFR (C677T, A1298C), FV Leiden polymorphisms, and the prothrombin G20210A mutation in arterial ischemic stroke among young tunisian adults.

Authors:  Lamia M'barek; Salma Sakka; Fatma Meghdiche; Dhaker Turki; Khadija Maalla; Mariem Dammak; Choumous Kallel; Chokri Mhiri
Journal:  Metab Brain Dis       Date:  2021-01-05       Impact factor: 3.584

Review 6.  Phenotypic Heterogeneity in Patients with Homozygous Prothrombin 20210AA Genotype. A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David Bosler; Joan Mattson; Domnita Crisan
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

7.  Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura.

Authors:  M-A von Mach; A Eich; L S Weilemann; T Münzel
Journal:  Heart       Date:  2005-02       Impact factor: 5.994

Review 8.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

9.  A potential regulatory role for mRNA secondary structures within the prothrombin 3'UTR.

Authors:  Xingge Liu; Yong Jiang; J Eric Russell
Journal:  Thromb Res       Date:  2010-08       Impact factor: 3.944

10.  Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile.

Authors:  S Koutroumpi; V Daidone; M T Sartori; M G Cattini; N M Albiger; G Occhi; S Ferasin; A Frigo; F Mantero; A Casonato; C Scaroni
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.